Covered recipient · General Payments record
RALPH JONATHAN HENDERSON
Allopathic & Osteopathic Physicians Urology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$43,066.43
77 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $13,250.00 | 5 |
| Travel and Lodging | $9,927.69 | 15 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,350.00 | 3 |
| Honoraria | $6,950.00 | 6 |
| Food and Beverage | $3,588.74 | 48 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $15,173.35 | 19 |
| SN Holdings, LLC | $11,202.84 | 18 |
| Bayer HealthCare Pharmaceuticals Inc. | $8,944.52 | 18 |
| Astellas Pharma US Inc | $3,364.07 | 4 |
| Photocure Inc | $3,000.00 | 1 |
| AstraZeneca Pharmaceuticals LP | $930.00 | 1 |
| Myovant Sciences Inc. | $231.43 | 8 |
| Blue Earth Diagnostics Limited | $81.90 | 3 |
| Merck Sharp & Dohme LLC | $67.68 | 1 |
| Antares Pharma, Inc. | $18.70 | 1 |
| Myriad Genetic Laboratories, Inc. | $18.47 | 1 |
| ABBVIE INC. | $18.02 | 1 |
| Axonics, Inc. | $15.45 | 1 |
Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RALPH JONATHAN HENDERSON
NPI 1164427621 · CMS profile ID 681317
Allopathic & Osteopathic Physicians / Urology
SHREVEPORT, LA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1164427621?year=2022&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RALPH JONATHAN HENDERSON, NPI 1164427621, CMS profile ID 681317. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1164427621?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). RALPH JONATHAN HENDERSON, NPI 1164427621, CMS profile ID 681317. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1164427621?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- RALPH JONATHAN HENDERSON, NPI 1164427621, CMS profile ID 681317, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1164427621?year=2022&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
77 matching records · $43,066.43 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–77 of 77.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $4.54 | 06/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930624819 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $87.75 | 06/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930626687 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $74.25 | 06/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930628159 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $3,234.00 | 06/24/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930628571 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $284.60 | 06/23/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930625293 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $121.46 | 06/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930626907 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $242.10 | 06/23/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930627361 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $276.64 | 06/23/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930627669 | CMS |
| Janssen Biotech, Inc. | $91.44 | 06/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885968663 | CMS |
| SN Holdings, LLC | $24.03 | 06/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 942783601 | CMS |
| SN Holdings, LLC | $267.11 | 06/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 942783605 | CMS |
| SN Holdings, LLC | $1,325.72 | 06/16/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 942783617 | CMS |
| Antares Pharma, Inc. | $18.70 | 06/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 956842893 | CMS |
| Myovant Sciences Inc. | $19.63 | 06/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941210439 | CMS |
| Blue Earth Diagnostics Limited | $47.49 | 06/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 961139397 | CMS |
| Janssen Biotech, Inc. | $31.25 | 06/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885968659 | CMS |
| Janssen Biotech, Inc. | $4,125.00 | 05/23/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885968593 | CMS |
| Astellas Pharma US Inc | $21.82 | 05/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940192271 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $18.44 | 05/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930602859 | CMS |
| Janssen Biotech, Inc. | $717.92 | 05/10/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885968587 | CMS |
| Blue Earth Diagnostics Limited | $17.80 | 05/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 961139347 | CMS |
| Janssen Biotech, Inc. | $1,100.00 | 04/25/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885968581 | CMS |
| Myovant Sciences Inc. | $13.49 | 04/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941210437 | CMS |
| Janssen Biotech, Inc. | $37.64 | 04/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885968681 | CMS |
| Myriad Genetic Laboratories, Inc. | $18.47 | 03/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937247041 | CMS |
| Janssen Biotech, Inc. | $57.34 | 03/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885968687 | CMS |
| Janssen Biotech, Inc. | $2.68 | 02/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885968653 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $548,548.25 | 69 |
| PY2024 | Principal investigator | $1,180,290.05 | 117 |
| PY2023 | Principal investigator | $174,462.66 | 23 |
| PY2022 | Principal investigator | $45,668.00 | 20 |
| PY2021 | Principal investigator | $1,064,527.24 | 102 |
| PY2020 | Recipient | $72.50 | 1 |
| PY2020 | Principal investigator | $328,338.15 | 92 |
| PY2019 | Principal investigator | $434,065.39 | 93 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
69 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $35,071.00 | 12/29/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175420653 |
| Principal investigator 1 | Ortho-Clinical Diagnostics, Inc. | $31,200.00 | 12/29/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER LLC | VITROS Immunodiagnostic Products Total PSA III Aid in Management Intended Use Sample Collection, | No dispute reported | 06/30/2026 | 1249804386 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,112.50 | 12/16/2025 | Non-covered Recipient Entity Arkansas Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175164174 |
| Principal investigator 1 | Janssen Research & Development, LLC | $510.00 | 12/15/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175420799 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,500.00 | 12/15/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175420883 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,173.00 | 12/09/2025 | Non-covered Recipient Entity Arkansas Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175164437 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,020.00 | 12/01/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175420664 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,390.00 | 12/01/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175420688 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,385.00 | 12/01/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175420908 |
| Principal investigator 1 | PFIZER INC. | $1,980.50 | 11/14/2025 | Non-covered Recipient Entity Arkansas Urology Research | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER | No dispute reported | 06/30/2026 | 1228728703 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,102.00 | 11/03/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175420713 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,675.00 | 11/03/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175420834 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,728.00 | 11/03/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175420871 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,020.00 | 11/03/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175420991 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,173.00 | 10/28/2025 | Non-covered Recipient Entity Arkansas Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175164384 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,760.00 | 10/24/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175420898 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,385.00 | 10/17/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175420700 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,390.00 | 10/06/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175420693 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,323.00 | 10/02/2025 | Non-covered Recipient Entity Arkansas Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175164624 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,564.00 | 10/02/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175420918 |
| Principal investigator 1 | PFIZER INC. | $7,920.95 | 09/16/2025 | Non-covered Recipient Entity Arkansas Urology Research | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER | No dispute reported | 06/30/2026 | 1228761421 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,385.00 | 09/15/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175420659 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,889.00 | 09/15/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175420772 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25,596.00 | 09/08/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175420760 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,112.50 | 09/05/2025 | Non-covered Recipient Entity Arkansas Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175164151 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,826.00 | 08/14/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175420809 |
| Principal investigator 1 | PFIZER INC. | $10,556.00 | 07/30/2025 | Non-covered Recipient Entity Arkansas Urology Research | A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF PF06821497 MEVROMETOSTAT WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER MEVPRO2 | No dispute reported | 06/30/2026 | 1228772390 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,336.00 | 07/28/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175420669 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,010.00 | 07/04/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175420827 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $24,250.00 | 07/02/2025 | Non-covered Recipient Entity Arkansas Urology-Little Rock | Validating The Guidelines-Based Care Pathway For Prostate Cancer | No dispute reported | 06/30/2026 | 1174940966 |
| Principal investigator 1 | PFIZER INC. | $3,018.00 | 06/27/2025 | Non-covered Recipient Entity Arkansas Urology Research | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER | No dispute reported | 06/30/2026 | 1228778605 |
| Principal investigator 1 | Janssen Research & Development, LLC | $510.00 | 06/20/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175420942 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,145.00 | 06/16/2025 | Non-covered Recipient Entity Arkansas Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175164376 |
| Principal investigator 1 | PFIZER INC. | $522.50 | 06/14/2025 | Non-covered Recipient Entity Arkansas Urology Research | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER | No dispute reported | 06/30/2026 | 1228792336 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,390.00 | 06/09/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175420815 |
| Principal investigator 1 | Janssen Research & Development, LLC | $24,378.00 | 06/06/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca | No dispute reported | 06/30/2026 | 1175420737 |
| Principal investigator 1 | Janssen Research & Development, LLC | $170.00 | 06/02/2025 | Non-covered Recipient Entity Arkansas Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175164536 |
| Principal investigator 1 | Janssen Research & Development, LLC | $125.00 | 06/02/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175420921 |
| Principal investigator 1 | Janssen Research & Development, LLC | $510.00 | 05/22/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175420725 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,826.00 | 05/22/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175420766 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,385.00 | 05/22/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175420877 |
| Principal investigator 1 | IBSA Institut Biochimique SA | $2,000.00 | 05/14/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) | No dispute reported | 06/30/2026 | 1223439063 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,770.00 | 05/12/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175420720 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,489.00 | 05/12/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175420732 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,519.00 | 05/01/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175420965 |
| Principal investigator 1 | PFIZER INC. | $2,115.50 | 04/29/2025 | Non-covered Recipient Entity Arkansas Urology Research | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER | No dispute reported | 06/30/2026 | 1228780439 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,173.00 | 04/28/2025 | Non-covered Recipient Entity Arkansas Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175164351 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,843.50 | 04/28/2025 | Non-covered Recipient Entity Arkansas Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175164513 |
| Principal investigator 1 | Janssen Research & Development, LLC | $34,801.00 | 04/28/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175420749 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 04/11/2025 | Non-covered Recipient Entity Arkansas Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175164571 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25,082.00 | 04/07/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175420682 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,687.00 | 04/04/2025 | Non-covered Recipient Entity Arkansas Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175164711 |
| Principal investigator 1 | PFIZER INC. | $472.50 | 03/28/2025 | Non-covered Recipient Entity Arkansas Urology Research | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER | No dispute reported | 06/30/2026 | 1228797278 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,020.00 | 03/14/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175420972 |
| Principal investigator 1 | Janssen Research & Development, LLC | $510.00 | 03/13/2025 | Non-covered Recipient Entity Arkansas Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175164688 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,117.00 | 03/13/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175420792 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,762.00 | 03/10/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175420708 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,634.00 | 03/07/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175420784 |
| Principal investigator 1 | Janssen Research & Development, LLC | $510.00 | 02/24/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175420845 |
| Principal investigator 1 | PFIZER INC. | $1,128.60 | 02/20/2025 | Non-covered Recipient Entity Arkansas Urology | A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF PF06821497 MEVROMETOSTAT WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER MEVPRO2 | No dispute reported | 06/30/2026 | 1228725514 |
| Principal investigator 1 | PFIZER INC. | $853.20 | 02/20/2025 | Non-covered Recipient Entity Arkansas Urology | A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF PF06821497 MEVROMETOSTAT WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER MEVPRO2 | No dispute reported | 06/30/2026 | 1228733348 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,750.00 | 02/13/2025 | Non-covered Recipient Entity Arkansas Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175164591 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,279.00 | 02/12/2025 | Non-covered Recipient Entity Arkansas Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175164462 |
| Principal investigator 1 | Janssen Research & Development, LLC | $27,532.00 | 02/10/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175420840 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,455.00 | 02/10/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175420904 |
| Principal investigator 1 | PFIZER INC. | $10,900.00 | 01/25/2025 | Non-covered Recipient Entity Arkansas Urology Research | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER | No dispute reported | 06/30/2026 | 1228801572 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $5,000.00 | 01/23/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER LLC | A Phase 4, Multi-center, Open Label Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose | No dispute reported | 06/30/2026 | 1242060116 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,092.00 | 01/13/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175420891 |
| Principal investigator 1 | Janssen Research & Development, LLC | $30,730.00 | 01/02/2025 | Non-covered Recipient Entity ARKANSAS UROLOGY RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175420997 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2024 | Amount invested | $0.00 | 2 |
| PY2024 | Value of interest | $75,352.94 | 2 |
| PY2023 | Amount invested | $0.00 | 1 |
| PY2023 | Value of interest | $73,877.15 | 1 |
| PY2022 | Amount invested | $0.00 | 1 |
| PY2022 | Value of interest | $35,664.83 | 1 |
| PY2021 | Amount invested | $0.00 | 1 |
| PY2021 | Value of interest | $33,117.34 | 1 |
| PY2020 | Amount invested | $0.00 | 1 |
| PY2020 | Value of interest | $84,916.31 | 1 |
| PY2019 | Amount invested | $0.00 | 1 |
| PY2019 | Value of interest | $64,952.25 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
7 records · PY2019–2024
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2024 | SN Holdings, LLC | $0.00 | $192.07 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1124771469 |
| PY2024 | SN Holdings, LLC | $0.00 | $75,160.87 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1124773217 |
| PY2023 | SN Holdings, LLC | $0.00 | $73,877.15 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1032887233 |
| PY2022 | SN Holdings, LLC | $0.00 | $35,664.83 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 941609231 |
| PY2021 | SN Holdings, LLC | $0.00 | $33,117.34 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 820124965 |
| PY2020 | UroGPO LLC | $0.00 | $84,916.31 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 737139477 |
| PY2019 | UroGPO LLC | $0.00 | $64,952.25 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 690775057 |